Details for New Drug Application (NDA): 206811
✉ Email this page to a colleague
NDA 206811 describes DALFAMPRIDINE, which is a drug marketed by Accord Hlthcare, Actavis Labs Fl Inc, Alkem Labs Ltd, Aurobindo Pharma, Hikma, Micro Labs, Rising, and Sun Pharm, and is included in eight NDAs. It is available from eight suppliers. Additional details are available on the DALFAMPRIDINE profile page.
The generic ingredient in DALFAMPRIDINE is dalfampridine. There are ten drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dalfampridine profile page.
The generic ingredient in DALFAMPRIDINE is dalfampridine. There are ten drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dalfampridine profile page.
Summary for 206811
| Tradename: | DALFAMPRIDINE |
| Applicant: | Aurobindo Pharma |
| Ingredient: | dalfampridine |
| Patents: | 0 |
Pharmacology for NDA: 206811
| Mechanism of Action | Potassium Channel Antagonists |
Suppliers and Packaging for NDA: 206811
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DALFAMPRIDINE | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 206811 | ANDA | Aurobindo Pharma Limited | 65862-863 | 65862-863-01 | 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-863-01) |
| DALFAMPRIDINE | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 206811 | ANDA | Aurobindo Pharma Limited | 65862-863 | 65862-863-05 | 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-863-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 10MG | ||||
| Approval Date: | Jan 23, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
